Representative Director & Senior Managing Executive Officer Kunio Nozaki PLAY LIST from the beginning Financial Results for FY2017 & Outlook for FY2018 (Cautionary Statement)(Slide only) Contents(Slide only) 1.Consolidated Financial Results for FY2017 Ended March 31, 2018 Voluntary adoption of IFRS Financial Summary IFRS Financial Summary J-GAAP Impact from Adoption of IFRS Sales revenue by Business segment Core Operating Income by Business segment Petrochemicals & Plastics - Segment Analysis - Energy & Functional Materials - Segment Analysis - IT-related Chemicals - Segment Analysis - Health & Crop Sciences - Segment Analysis - Pharmaceuticals - Segment Analysis - Breakdown of Non-core Items Consolidated Balance Sheets Consolidated Statements of Cash Flows 2.Outlook for FY2018 Financial Summary Sales revenue by Business segment Core Operating Income by Business segment Analysis of Core Operating Income Petrochemicals & Plastics - Segment Analysis - Energy & Functional Materials - Segment Analysis - IT-related Chemicals - Segment Analysis - Health & Crop Sciences - Segment Analysis - Pharmaceuticals - Segment Analysis - Consolidated Statements of Cash Flows (Reference: Segment Information) Segment Topics Sales revenue by Business segment I (Quarterly) Sales revenue by Business segment II (Quarterly) Operating Income /Core Operating Income by Business segment I (Quarterly) Core Operating Income by Business segment II (Quarterly) Cost Elements etc. Capital Expenditures by Business segment Estimated Capital Expenditures by Business segment Depreciation and Amortization by Business segment Estimated Depreciation and Amortization by Business segment Research & Development Expenses by Business segment Estimated Research & Development Expenses by Business segment Major Group Companies Overseas Sales revenue Sales revenue / Profits Transition Interest-bearing Liabilities / D/E Ratio Transition Cash Dividends / Payout Ratio Transition Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Back Next